SI-BONESIBN
Recorded

SI-BONE UBS Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration35 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Patrick WoodAnalyst

All righty. Thank you so much, everybody, for joining. Really appreciate it. Obviously, Patrick on the U.S. MedTech team. Last session of the day, and very excited. Anshul, as Chief Financial Officer here from SI-BONE. Thanks so much for agreeing to come to do this.

Anshul MaheshwariCFO

No, thanks for having us here.

Patrick WoodAnalyst

You guys have a lot going on, and before I dive into the sort of specific questions, I would love to just get a sort of state of the union for you, how you feel about the business. A lot has changed in the last few years. No particular direction, just how does it feel?

Anshul MaheshwariCFO

When you think about our business over the last several years, we started with being an anatomy-specific company within the pelvis, and we built a franchise there with SI joint dysfunction. Then we went into pelvic fixation and then pelvic trauma. The common thread there was we were focused on unmet clinical needs, which is where SI joint dysfunction play in, and/or areas where the current standard of care was very poor and you had high failure rates, which is where pelvic fixation came into play and pelvic trauma came into play. And we have seen a great amount of success there, and I am happy to walk through some metrics in a minute on that.

Anshul MaheshwariCFO

But since that, what we've been very focused on is saying, "What is our core competency as we look at the future of the company?" Our core competencies revolve around being able to fix and fuse low-density bone. That was number one. Number two was the biomechanical and 3D printing expertise, design expertise that we had developed. Number three was being able to, since you were going after unmet clinical needs, being focused on clinical evidence. Number four, when you're building out the market, making sure you had a level of reimbursement that could support the economics for the healthcare system while also improving the outcomes, which in the long run actually reduces the cost of the healthcare system.

Anshul MaheshwariCFO

As we looked at that, we started to broaden our aperture and started looking at opportunities within compromised bone, which generally would be patients with osteoporosis, osteopenia, or other sort of bone-compromising disease states. That really has allowed us to widen the level of opportunities we can go after. Onyx was the first product that we put out there. That was our first product outside the pelvis, and it's a very exciting opportunity for us, as you heard on our earnings call, but there's more to come. We've called ourselves being on an innovation super cycle start of the year. We launched a couple products already this year, and we are on this flywheel of continuing to launch products at a regular cadence going forward, at least one, maybe two products a year, each targeting a new SAM.

Anshul MaheshwariCFO

Again, the reason I use the word SAM is because we're going after unmet or disease states that have poor outcomes, these are well-defined SAMs. What we don't want to do is be a me-too product company, and by focusing on specific failure rates, we're actually going after markets that we can own and that we can define.

Patrick WoodAnalyst

I'd love to start actually with Onyx. It seems like the obvious thing to jump into. Maybe to just to level set everybody, because there might be some people in the room who are less familiar, can you just give a quick overview of Onyx as a platform and what you're doing there?

Anshul MaheshwariCFO

Sure. Again, if you think about what we've been able to do in the last few years with, I will start with Granite, but our overall innovation cycle has been focused on where can we improve outcomes for patients and reduce failure rates. We started with Granite in complex fusion. That was about four years ago. That was going at the base of deformity and degen constructs that end at the pelvis. There was a 24% failure rate for those procedures. Granite, we believe, is starting to become the standard of care. It was our first breakthrough device. We recently put out a clinical study, PAULA, that actually showed the revision rate went down from 24% to around 3% in cases where Granite was used.

Anshul MaheshwariCFO

What we did was we leveraged that same technology and said, "Okay, what else can we address within the spine fusion space or complex fusion space for our customers?" The next failure opportunity that we wanted to go after was UIV and LIV, which is upper instrumented vertebra, lower instrumented vertebra. Simplistically, think about it as the top of the construct and the bottom of the construct. Literature would tell you there is about a 27% failure rate in those procedures, so it is quite high. It is actually even more elevated for patients that have osteoporosis just because you do not have the bone to fuse or bite into and fix into. Onyx is going after that need. It is a massive opportunity for us. Our best estimate is around 200,000 annual procedures would benefit from Onyx, and about a quarter of that is in the deformity space.

Anshul MaheshwariCFO

The remainder of that is in the degen space. So very attractive opportunity. It is with the same call point that today uses Granite. It is within the same commercial channel that today sells Granite, and it has got a lot of reimbursement frameworks already set up, especially when you think about complex fusion procedures, which are seven or more level. They will be able to benefit from the new DRGs that were effective October 1st. Because it is another breakthrough device, this is our third breakthrough device, we have also filed for NTAP, which, if approved, would go effective October 1st, 2027. So a great opportunity with a well-known issue from our customers, fits within the channel, has the infrastructure that we worked on to build over the last four years to really drive growth acceleration for the business.

Patrick WoodAnalyst

You guys flagged on the Q3 call the encouraging alpha launch from the start of it. What do you learn about patient selection and surgeon demand from that alpha launch?

Anshul MaheshwariCFO

Yeah, so we got FDA clearance at the end of September, and we did our first case then, and we've been in alpha launch since then, which is a small group of surgeons that we're going out and working with right now, just to make sure that we've really simplified the workflow that fits with them, and everything is working as it should. We basically had three metrics that we're tracking to define the success of Onyx. Number one is Onyx being used in cases with Granite? Because it's the same call point, a lot of times the same procedure. The answer to that is yes. Number two was not all cases that we work on with Granite, not all of the cases go to the pelvis, right? There's about 400-plus thousand fusion procedures. There's around 50,000 or 40,000 to 50,000 deformity procedures.

Anshul MaheshwariCFO

On the deformity side, we think all of them should go to the pelvis. On the fusion side, in degen, not all of them do go to the pelvis. So our second metric was physicians that do not use Granite in all the cases, will they use Onyx? The answer to that was yes. That allows us to get more cases per physician. Then the third aspect of our success was physicians who today don't use Granite at all because they don't go to the pelvis, mostly in the degen side, can we see success with Onyx? And the answer to that is yes. So, if you think about the three big metrics for us, one is, can we get higher procedure ASP? In month one, we are seeing that. Number two is, can we get more cases per physician? We are seeing that. And number three, can we continue to attract new physicians who today do not use Granite to be able to use Onyx?

Anshul MaheshwariCFO

So the answer to that is yes as well. But it's month one. It is an alpha launch. We are going to do a beta launch as we go throughout the quarter, and then we'll do full launch in Q1, and then continue to roll out surgical capacity throughout the first half of the year. So, really pleased with what we see. And the other benchmark, and we talked about this during our earnings, Granite has been a great success for us, and it's been one of the fastest scaling platforms for us in the last four years.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day